SBC Medical Group Holdings Inc., Japan's leading aesthetic medical clinic operator, has entered into an e-consulting agreement with BLEZ ASIA Co., Ltd. to expand its operations into Thailand. The partnership will establish a new dermatological clinic in Bangkok's Asok district, scheduled to open by year-end, representing SBC's second international expansion following its 2024 entry into Singapore.
The Thai aesthetic medicine market presents substantial growth potential, with demand projected to reach nearly $1.2 billion by 2033, growing at a compound annual growth rate of 13.5%. Thailand's fragmented market of small-scale operators providing inconsistent service, combined with a Japanese expatriate population of approximately 60,000 seeking Japanese-quality treatments, creates ideal conditions for SBC's expansion strategy. BLEZ ASIA operates more than twenty pharmacies and clinics in Thailand and maintains strong trust among both Japanese expatriates and local patients.
Under the agreement, SBC will provide comprehensive management support to the new clinic, advising on clinical protocols aligned with SBC's quality standards and assisting in selecting medical devices and treatment methods optimized for local skin characteristics and environmental conditions. The clinic will primarily focus on dermatological treatments such as pigmentation and spot removal, addressing the growing demand for specialized skin care services in the region.
Yoshiyuki Aikawa, CEO of SBC, emphasized the strategic importance of the move, stating that Japanese aesthetic medicine is globally competitive for its precision and high safety standards. Partnering with a trusted local leader like BLEZ in the fast-growing Thai market represents a significant step forward in SBC's Asia strategy. The company aims to create a model where Japan's advanced medical services can take root locally and deliver new value, beginning with the Japanese expatriate community before expanding to serve the broader Thai market.
The expansion comes as SBC reports strong performance in its domestic market, with annual patient visits growing 15% year-over-year in the third quarter and a return customer rate of 72%. The company recently overhauled its pricing structure to attract and retain customers while maintaining competitive positioning in Japan. Naoki Iida, CEO of BLEZ ASIA, noted that the Thai aesthetic medicine market continues to grow rapidly with increasing focus on quality and safety, making the partnership with SBC an invaluable opportunity to establish Japanese-standard, high-quality medical services in Thailand.
Both companies aim to address customer demand for high-quality, affordable aesthetic treatments that offer subtle, natural-looking enhancements with minimal downtime. The collaboration seeks to build a brand trusted and loved by the community for years to come, combining SBC's medical expertise with BLEZ ASIA's local market knowledge and established reputation. This expansion represents SBC's continued commitment to providing consistently high-level medical services while establishing new value in international aesthetic medicine markets.
